Hey Everest, welcome (publicly) to the board. Love the name, by the way.
From what I can tell, nobody has a definitive answer here and the company isn't talking for the moment. Last we heard, a few months back they had seven patients. No official updates on that front, so they could have seven patients or they could have filled up a month ago. A couple of thoughts that have been kicked around though.
- Pearsby thinks they haven't been able to enroll anyone. But you already knew that from following the board.
- There was a Q&A a while back with Dr. Pourhassen that suggested that getting sites enrolled took time, then the patients had to be identified and enrolled after that. Some of us probably conflate the time for those two separate activities, making it seem like a longer wait. They had stopped getting sites online while they were negotiating the adjunct protocol with the FDA. I can try to find the link, but it's already referenced in one of my posts on this board I believe.
- Good, clean data is paramount, as you know. Some speculate that they're being hyper vigilant about getting the exact right patients to make sure that they have the best possible results. This makes some sense given the reduced size of the trial - a "random" error caused by sub-par screening would have an outsize effect on PE. Management may be less worried about a few extra weeks here and there than they are about absolutely nailing the adjunct data.
- They could already be fully enrolled and completed, and potentially even have successful PE's in hand. As Chump and others have discussed, getting the stock uplisted is crucial. Having several elements of good news on tap would help the SP to a point where they could uplist before shorts drove it back down. The gamesmanship argument here is certainly plausible, but I'm sure there's a relatively short window on how long they can sit on material information such as positive or negative PE's.
Disclaimer: I don't know anything or suggest that one of these possibilities is more likely than any other, these are just ideas that have been floated on the board by smarter people than me. Well, mostly.
